Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Molecular pathology and cystogenic propensity of the ADPKD Taiwan founder variant
Louise F. Kimura, Orhi Esarte Palomero, Megan Larmore, Paul G. DeCaen, Thuy N. Vien
Louise F. Kimura, Orhi Esarte Palomero, Megan Larmore, Paul G. DeCaen, Thuy N. Vien
View: Text | PDF
Research Article Cell biology Nephrology

Molecular pathology and cystogenic propensity of the ADPKD Taiwan founder variant

  • Text
  • PDF
Abstract

Renal polycystins (PKD1, PKD2) are ion channel–forming subunits that traffic to principal cell primary cilia. Variants in these proteins cause approximately 95% of autosomal dominant polycystic kidney disease (ADPKD), a common, lethal genetic disorder that lacks effective drug treatments. We assessed the mechanistic impact and pathogenic propensity of 2 disease-associated PKD2 truncating variants, R803X and R654X. Worldwide, hundreds of individuals with ADPKD harbor these germline mutations, including the R803X founder variant first identified within the patient population of Taiwan. Our biochemical, electrophysiological, and super-resolution imaging analyses demonstrated that the pore-truncating R654X variant abolished channel assembly and ciliary trafficking, whereas the R803X variant retained partial cilia trafficking and channel function. To assess disease impact, we generated transgenic mice with analogous truncation mutations. Homozygous mutants were embryonic lethal, whereas heterozygous mice expressing both variant and conditional Pkd2 repression alleles developed pronounced renal cysts. Cyst progression was slower in mice carrying the equivalent Taiwan mutation, reflecting the milder clinical course observed in patients. These findings revealed that the degree of impaired PKD2 channel trafficking to primary cilia correlated with cystic disease severity, providing insight into variant-specific ADPKD pathogenesis and newly developed animal models expressing clinically relevant variants for therapeutic testing.

Authors

Louise F. Kimura, Orhi Esarte Palomero, Megan Larmore, Paul G. DeCaen, Thuy N. Vien

×

Figure 1

Two-hit hypothesis of ADPKD cyst initiation and the worldwide distribution of the Taiwan founder variant.

Options: View larger image (or click on image) Download as PowerPoint
Two-hit hypothesis of ADPKD cyst initiation and the worldwide distributi...
(A) Diagram depicting the germline polycystin gene alleles impacted in 95% of ADPKD clinical cases and the acquisition of a second somatic mutation that drives ADPKD progression. Note, ADPKD does not progress until a second acquired mutation impacts either PKD1 or PKD2 alleles. (B) Geographic distribution of the PKD2 R801X truncation variant based on patient sequencing analysis from 25 institutions and 17 countries (29). Expanded view: Published analysis of a cohort of ADPKD patients in Taiwan identifying the PKD2 R801X founder variant (30). Note the high frequency of PKD2 germline mutations (32%) within the Taiwanese patient population compared with that observed globally (~15%). Map images were created with MapChart (https://www.mapchart.net/) under a Creative Commons Attribution–Share Alike 4.0 International License. (C) Top: Previously determined PKD2 channel core structures solved by cryo-EM (24, 40, 78, 79). Bottom: The isolated C-terminal EF hand and coiled-coil motif structures solved by NMR and x-ray crystallography, respectively (41, 42, 49). (D) Left: Assembled homotetrameric PKD2 channel AlphaFold3 models. Right: A PKD2 subunit modeled using AlphaFold3 identifying the structural location of R654 and R803 variant sites, and integral structural motifs.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts